yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q35528797-88ACE0E8-C82A-46A8-B7EA-A2E3C4CF8652
Q35528797-88ACE0E8-C82A-46A8-B7EA-A2E3C4CF8652
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35528797-88ACE0E8-C82A-46A8-B7EA-A2E3C4CF8652
Short commentary on empagliflozin and its potential clinical impact
P2860
Q35528797-88ACE0E8-C82A-46A8-B7EA-A2E3C4CF8652
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35528797-88ACE0E8-C82A-46A8-B7EA-A2E3C4CF8652
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
502c7850572ed135cc87a7b6baf67775cfed1da4
P2860
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.